Trinity Legacy Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-6,866
Closed -$252K 108
2023
Q2
$252K Sell
6,866
-100,246
-94% -$3.9M 0.09% 69
2023
Q1
$4.37M Sell
107,112
-236
-0.2% -$10.2K 1.64% 26
2022
Q4
$5.5M Buy
107,348
+3,838
+4% +$184K 2.19% 15
2022
Q3
$4.53M Buy
103,510
+3,171
+3% +$154K 1.94% 19
2022
Q2
$5.31M Sell
100,339
-10,020
-9% -$511K 2.06% 12
2022
Q1
$5.71M Buy
110,359
+12,768
+13% +$662K 1.93% 15
2021
Q4
$5.76M Buy
97,591
+889
+0.9% +$44K 1.95% 15
2021
Q3
$4.16M Buy
96,702
+5,016
+5% +$222K 1.49% 19
2021
Q2
$3.63M Buy
91,686
+3,931
+4% +$153K 1.34% 25
2021
Q1
$3.38M Buy
87,755
+5,030
+6% +$179K 1.35% 24
2020
Q4
$3.04M Buy
82,725
+73,025
+753% +$2.68M 1.38% 23
2020
Q3
$340K Buy
9,700
+1,370
+16% +$48K 0.16% 59
2020
Q2
$273K Buy
+8,330
New +$283K 0.14% 65
2020
Q1
Sell
-20,129
Closed -$743K 80
2019
Q4
$743K Buy
+20,129
New +$717K 0.35% 44

Other funds holding PFE

Trinity Legacy Partners's PFE Position: Q3 2023 in Review

Trinity Legacy Partners sold out of Pfizer (PFE) in Q3 2023, closing a stake of 6,866 shares — an estimated $252K sold.

Trinity Legacy Partners first reported a position in PFE in Q4 2019 and held it in 14 quarters. The position peaked at $5.76M in Q4 2021. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

  • Trinity Legacy Partners reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
  • Trinity Legacy Partners sold 6,866 Pfizer shares in Q3 2023, an estimated $252K.
  • Trinity Legacy Partners first reported a position in Pfizer in Q4 2019 and held it in 14 quarters.
  • Trinity Legacy Partners's Pfizer position peaked at $5.76M in Q4 2021.
  • 2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Trinity Legacy Partners's 13F filing for Q3 2023, filed 11 Oct 2023.